Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
106.49
+1.14 (1.08%)
At close: Aug 31, 2026, 4:00 PM EDT
106.50
+0.01 (0.01%)
After-hours: Aug 31, 2026, 7:58 PM EDT

Halozyme Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Revenue
481376.71451.77354.26325.72264.86298.01290.08231.35195.88230.04216.03221.04162.14181.5208.98152.37117.28102115.83
Revenue Growth
47.67%42.23%51.60%22.13%40.79%35.22%29.55%34.28%4.67%20.81%26.75%3.38%45.07%38.25%77.93%80.42%11.66%31.74%-16.19%77.34%
Gross Profit
374.16271.91341.1281.77261.82201.66235.51222.2170.71148.44156.41143.89151.24108.99116.81144.95102.9489.570.3188.76
Operating Income
287.65184.52254.4217.92202.44141.54175.5163.2117.2495.54101.0490.7894.4653.896.4183.2934.0675.6756.5375.59
Net Income
229.91150.05-141.59175.23165.16118.1137.01137.0193.2576.8285.3981.8474.7539.6257.761.6322.6960.1166.77216.59
Earnings Per Share
1.901.22-1.201.431.330.931.061.050.720.600.650.610.560.290.420.440.160.430.451.48
EPS Growth
42.86%31.18%-36.19%84.72%55.00%62.30%72.13%28.57%106.90%54.64%38.64%250.00%-32.56%-6.93%-70.27%-74.19%126.32%-9.31%492.00%

Revenue by Segment

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Royalties
307.7240.68257.97236.04205.64168.19170.42155.06124.92120.59122.05114.43111.7499.64105.9899.5585.3469.6162.6458.56
Sales of Proprietary Products
55.4341.8759.5752.2446.4536.3447.339.9344.1435.2539.0731.5132.2927.9628.2924.1814.695.695.816.19
Sales of Bulk rHuPH20
59.6273.550.2432.4923.2727.0319.731.4924.6310.5129.243727.1322.0721.3219.2625.0616.4521.2418.86
Sales of Device Partnered Products
14.5815.0512.869.511.7914.6812.3715.2410.1112.8211.2918.0614.4610.7611.5517.996.56---
Revenue Under Collaborative Agreements
43.675.671.132438.5718.6348.2348.3627.5516.728.3915.0335.411.7114.354820.7325.5312.3232.22
Revenue (Total)
481376.71451.77354.26325.72264.86298.01290.08231.35195.88230.04216.03221.04162.14181.5208.98152.37117.28102115.83

Cash & Debt

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Cash & Investments
231318.62142.82701.96548.18747.92596.07666.31529.03463.45336483.28348.28275.61362.79265.58209.36786.14740.92815.92
Total Debt
2,1792,1772,1771,5391,5381,5371,5061,5351,5331,5331,5311,5301,5301,5281,5411,5121,254879.85879.49879.13
Net Cash (Debt)
-1,948-1,858-2,034-836.9-989.89-788.91-909.72-868.6-1,004-1,069-1,195-1,047-1,181-1,253-1,178-1,246-1,045-93.71-138.57-63.21
Net Cash Growth
--------------------
Net Cash Per Share
-16.07-15.12-17.29-6.84-7.97-6.23-7.05-6.67-7.77-8.30-9.12-7.81-8.85-9.09-8.50-8.94-7.35-0.66-0.96-0.43

Cash Flow & CapEx

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Operating Cash Flow
240.89180.08219.03178.699.71154.22178.47115.3855.79129.43102.35132.4166.8486.9682.4569.6440.2347.882.52121.74
Capital Expenditures
-4.17-3.74-1.43-3.03-1.56-0.95-3.05-1.52-2.58-3.55-2.6-2.941.62-11.38-2.34-1.01-0.97-0.49-0.16-0.5
Free Cash Flow
236.72176.34217.6175.5798.15153.27175.42113.8653.21125.8899.76129.4768.4775.5980.1168.6339.2647.3182.36121.24
Free Cash Flow Growth
141.19%15.05%24.05%54.20%84.45%21.76%75.84%-12.06%-22.28%66.54%24.53%88.65%74.40%59.78%-2.73%-43.40%7.98%-18.47%67.32%1952.18%

Margins

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Gross Margin
77.79%72.18%75.50%79.54%80.38%76.14%79.03%76.60%73.79%75.78%67.99%66.61%68.42%67.22%64.36%69.36%67.56%76.32%68.93%76.63%
Operating Margin
59.80%48.98%56.31%61.51%62.15%53.44%58.89%56.26%50.67%48.78%43.92%42.02%42.73%33.18%53.12%39.86%22.35%64.52%55.42%65.26%
Pretax Margin
59.23%47.87%-22.32%61.81%62.92%54.30%59.80%56.93%50.89%49.02%43.98%47.10%42.14%32.22%39.00%35.27%19.70%63.45%53.73%63.98%
Profit Margin
47.80%39.83%-31.34%49.46%50.71%44.59%45.98%47.23%40.30%39.22%37.12%37.88%33.82%24.43%31.79%29.49%14.89%51.25%65.46%186.99%
FCF Margin
49.21%46.81%48.17%49.56%30.13%57.87%58.86%39.25%23.00%64.27%43.37%59.93%30.97%46.62%44.14%32.84%25.77%40.34%80.74%104.67%

Valuation

Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
PE Ratio
22.4521.95-14.4111.5016.2413.7018.4819.7616.2117.3419.8520.9028.4738.0625.8016.5612.6314.0514.15
Forward PE
8.858.068.8510.318.6412.6210.3812.7612.2811.049.7711.2011.8214.8221.9216.1619.2218.2417.8917.61
P/FCF Ratio
11.5211.4712.2814.2411.8615.9012.9918.4616.3212.2013.0814.2516.6819.6232.7022.9320.8919.1318.9921.85
PS Ratio
5.585.085.676.905.447.275.997.657.635.995.896.466.317.3411.669.3812.4411.6512.7612.50